ibrutinib,venetoclax,Obinutuzumab,rituximab
roche,janssen,abbvie,biogen
['obinu', 'ibru', 'venetoclax', 'rituximab', 'cll']
very interesting cll13 results at #eha2022
addition of ibrutinib does not impact in pfs with current follow up, and is more toxic
clear benefit of obinutuzumab over rituximab in combination with venetoclax 
MD, PhD
Hematologist at Hospital Universitario de Salamanca